tradingkey.logo

Clearpoint Neuro Inc

CLPT
13.460USD
+0.890+7.08%
Handelsschluss 02/06, 16:00ETKurse um 15 Minuten verzögert
382.64MMarktkapitalisierung
VerlustKGV TTM

Clearpoint Neuro Inc

13.460
+0.890+7.08%

mehr Informationen über Clearpoint Neuro Inc Unternehmen

ClearPoint Neuro, Inc. is a device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. The Company provides both clinical products as well as pre-clinical development services for controlled drug and device delivery. Its flagship product is the ClearPoint Neuro Navigation System. The Company is engaged with healthcare and research centers in North America, Europe, Asia, and South America. Its primary medical device product, the ClearPoint system, is an integrated system comprised of hardware components, disposable components, and intuitive, menu-driven software. Its ClearPoint Prism Neuro Laser Therapy System is indicated for use to necrotize or coagulate soft tissue through interstitial irradiation or thermal therapy for neuro applications under 3.0T magnetic resonance imaging (MRI) guidance. The Company also provides solutions for direct CNS delivery of therapeutics in preclinical studies and clinical trials worldwide.

Clearpoint Neuro Inc Informationen

BörsenkürzelCLPT
Name des UnternehmensClearpoint Neuro Inc
IPO-datumJul 03, 2019
CEOBurnett (Joseph Michael)
Anzahl der mitarbeiter115
WertpapierartOrdinary Share
GeschäftsjahresendeJul 03
Addresse120 S. Sierra Avenue
StadtSOLANA BEACH
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl92075
Telefon19499006833
Websitehttps://www.clearpointneuro.com/
BörsenkürzelCLPT
IPO-datumJul 03, 2019
CEOBurnett (Joseph Michael)

Führungskräfte von Clearpoint Neuro Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Joseph Michael Burnett
Mr. Joseph Michael Burnett
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
276.33K
--
Mr. Timothy T. Richards
Mr. Timothy T. Richards
Independent Director
Independent Director
79.75K
+884.00%
Dr. Matthew B. Klein, M.D.
Dr. Matthew B. Klein, M.D.
Independent Director
Independent Director
50.52K
+21093.00%
Mr. Mazin Sabra
Mr. Mazin Sabra
Chief Operating Officer
Chief Operating Officer
44.47K
+386.00%
Ms. Lynnette C. Fallon
Ms. Lynnette C. Fallon
Independent Director
Independent Director
40.90K
-10200.00%
Mr. Pascal E.R. Girin
Mr. Pascal E.R. Girin
Independent Director
Independent Director
--
--
Mr. R. John Fletcher
Mr. R. John Fletcher
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. B. Kristine (Kris) Johnson
Ms. B. Kristine (Kris) Johnson
Independent Director
Independent Director
--
--
Mr. Danilo D' Alessandro
Mr. Danilo D' Alessandro
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Linda M. Liau
Dr. Linda M. Liau
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Joseph Michael Burnett
Mr. Joseph Michael Burnett
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
276.33K
--
Mr. Timothy T. Richards
Mr. Timothy T. Richards
Independent Director
Independent Director
79.75K
+884.00%
Dr. Matthew B. Klein, M.D.
Dr. Matthew B. Klein, M.D.
Independent Director
Independent Director
50.52K
+21093.00%
Mr. Mazin Sabra
Mr. Mazin Sabra
Chief Operating Officer
Chief Operating Officer
44.47K
+386.00%
Ms. Lynnette C. Fallon
Ms. Lynnette C. Fallon
Independent Director
Independent Director
40.90K
-10200.00%
Mr. Pascal E.R. Girin
Mr. Pascal E.R. Girin
Independent Director
Independent Director
--
--

Umsatzaufteilung

Währung: USDAktualisiert: Tue, Jan 6
Währung: USDAktualisiert: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Products: Functional neurosurgery
3.42M
38.62%
Services: Biologics and drug delivery
3.11M
35.10%
Products: Biologics and drug delivery
1.29M
14.58%
Product Systems and software products
647.00K
7.30%
Services: Capital equipment and other
390.00K
4.40%
Nach RegionUSD
Name
Umsatz
Anteil
United States
8.86M
100.00%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Products: Functional neurosurgery
3.42M
38.62%
Services: Biologics and drug delivery
3.11M
35.10%
Products: Biologics and drug delivery
1.29M
14.58%
Product Systems and software products
647.00K
7.30%
Services: Capital equipment and other
390.00K
4.40%

Aktionärsstatistik

Aktualisiert: Fri, Feb 6
Aktualisiert: Fri, Feb 6
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
5.94%
BlackRock Institutional Trust Company, N.A.
5.47%
Bigger Capital Funds, LP
4.48%
PTC Therapeutics Inc
3.01%
Geode Capital Management, L.L.C.
2.21%
Andere
78.90%
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
5.94%
BlackRock Institutional Trust Company, N.A.
5.47%
Bigger Capital Funds, LP
4.48%
PTC Therapeutics Inc
3.01%
Geode Capital Management, L.L.C.
2.21%
Andere
78.90%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
21.26%
Investment Advisor/Hedge Fund
10.48%
Hedge Fund
8.69%
Individual Investor
4.99%
Corporation
3.01%
Research Firm
1.38%
Bank and Trust
0.10%
Pension Fund
0.03%
Insurance Company
0.03%
Andere
50.03%

Institutionelle Beteiligung

Aktualisiert: Mon, Dec 8
Aktualisiert: Mon, Dec 8
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
238
11.91M
42.82%
-795.00
2025Q3
241
11.91M
44.93%
+805.07K
2025Q2
228
11.11M
37.29%
+1.29M
2025Q1
216
9.82M
36.04%
-268.85K
2024Q4
204
9.20M
33.04%
+1.04M
2024Q3
190
8.15M
32.05%
-235.56K
2024Q2
185
8.39M
33.08%
-454.38K
2024Q1
183
8.85M
30.95%
+359.48K
2023Q4
183
7.82M
35.41%
+717.11K
2023Q3
184
7.11M
35.71%
+336.40K
Mehr Anzeigen

Aktionärsaktivitäten

Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
The Vanguard Group, Inc.
1.50M
5.03%
+22.52K
+1.53%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
1.63M
5.47%
+127.17K
+8.48%
Sep 30, 2025
Bigger Capital Funds, LP
1.29M
4.34%
+126.00K
+10.80%
Sep 30, 2025
PTC Therapeutics Inc
894.58K
3.01%
--
--
Aug 23, 2024
Geode Capital Management, L.L.C.
656.40K
2.21%
+31.60K
+5.06%
Sep 30, 2025
State Street Investment Management (US)
482.65K
1.62%
+149.27K
+44.77%
Sep 30, 2025
Two Sigma Investments, LP
442.93K
1.49%
+421.00K
+1919.91%
Sep 30, 2025
Bigger (Michael)
378.69K
1.27%
--
--
Sep 30, 2025
UBS Financial Services, Inc.
360.70K
1.21%
+205.29K
+132.10%
Sep 30, 2025
District 2 Capital LP
307.75K
1.03%
-122.42K
-28.46%
Sep 30, 2025
Mehr Anzeigen

Verbundene ETFs

Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
Invesco NASDAQ Future Gen 200 ETF
1.19%
iShares Neuroscience and Healthcare ETF
0.94%
iShares Micro-Cap ETF
0.12%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.09%
Vanguard US Momentum Factor ETF
0.06%
Motley Fool Next Index ETF
0.03%
Invesco Russell 2000 Dynamic Multifactor ETF
0.03%
iShares Russell 2000 Growth ETF
0.03%
iShares Russell 2000 ETF
0.02%
Proshares Ultra Russell 2000
0.02%
Mehr Anzeigen
Invesco NASDAQ Future Gen 200 ETF
Anteil1.19%
iShares Neuroscience and Healthcare ETF
Anteil0.94%
iShares Micro-Cap ETF
Anteil0.12%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Anteil0.09%
Vanguard US Momentum Factor ETF
Anteil0.06%
Motley Fool Next Index ETF
Anteil0.03%
Invesco Russell 2000 Dynamic Multifactor ETF
Anteil0.03%
iShares Russell 2000 Growth ETF
Anteil0.03%
iShares Russell 2000 ETF
Anteil0.02%
Proshares Ultra Russell 2000
Anteil0.02%

Dividende

In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten

Aktien-Split

Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
KeyAI